Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-47835
Theurillat, J P; Metzler, S C; Henzi, N; Djouder, N; Helbling, M; Zimmermann, A K; Jacob, F; Soltermann, A; Caduff, R; Heinzelmann-Schwarz, V; Moch, H; Krek, W (2011). URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell, 19(3):317-332.
- Registered users only
Abrogation of negative feedback control represents a fundamental requirement for aberrantly activated signaling pathways to promote malignant transformation and resistance to therapy. Here we identify URI, which encodes a mitochondrial inhibitor of PP1γ and PP1γ-mediated feedback inhibition of S6K1-BAD survival signaling, as an oncogene amplified and overexpressed in ovarian cancer cell lines and human ovarian carcinomas. URI is an "addicting" oncogene selectively required for the survival of ovarian cancer cells with increased URI copy number. By constitutively detaining PP1γ in inactive complexes, URI sustains S6K1 survival signaling under growth factor-limiting conditions and mediates resistance of cells to cisplatin. Thus, oncogenic activation of URI defines an important mechanism for activating mitochondrial S6K1-BAD signaling and promoting cell survival through disabling PP1γ-dependent negative feedback inhibition.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Institute of Surgical Pathology
04 Faculty of Medicine > University Hospital Zurich > Clinic for Gynecology
|DDC:||610 Medicine & health|
|Deposited On:||31 Mar 2011 11:11|
|Last Modified:||17 Jul 2014 15:49|
|Citations:||Web of Science®. Times Cited: 10|
Scopus®. Citation Count: 10
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page